Loading
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Previous close
$2.21
−$0.01 · -0.45%
Regular session · ET · Market data may be delayed.
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Day range
Current $2.21
52-week range
Current $2.21
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
33
Expensive
Sentiment
75
Bullish
Risk
59
Elevated Risk
Momentum
88
Strong Up
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Equillium, Inc. is a clinical-stage biopharmaceutical company focused on developing and bringing to market products designed to address severe autoimmune and inflammatory (immuno-inflammatory) disorders where current treatment options are insufficient. The company's primary drug candidate is itolizumab (EQ001), a monoclonal antibody in clinical development that targets the novel CD6 immune checkpoint receptor. Itolizumab is currently in Phase III trials for acute graft-versus-host disease, has completed Phase Ib studies for asthma, and is also undergoing Phase Ib trials for lupus nephritis. In addition to itolizumab, Equillium is advancing EQ101 for the treatment of cutaneous T cell lymphoma and alopecia areata, and EQ102, which targets various gastrointestinal conditions. Headquartered in La Jolla, California, the company was incorporated in 2017 and previously operated as Attenuate Biopharmaceuticals, Inc. before changing its name to Equillium, Inc. in May 2017.
Day range
Current $2.21
52-week range
Current $2.21
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 41.1M USD | 36.08M USD | 15.76M USD | — |
| Cost of goods sold | 116K USD | — | — | — | — |
| Gross profit | −116K USD | 41.1M USD | 36.08M USD | 15.76M USD | — |
| Research and development | 12.84M USD | 37.43M USD | 37.04M USD | 37.55M USD | 26.38M USD |
| Selling, general, and administrative | 10.79M USD | 11.94M USD | 13.57M USD | 17.24M USD | 11.41M USD |
| Operating expenses | 23.63M USD | 49.36M USD | 50.61M USD | 77.84M USD | 37.79M USD |
| Interest income | 833K USD | 1.38M USD | 2.33M USD | 420K USD | 57K USD |
| Interest expense | — | — | 491K USD | 1.05M USD | 1.07M USD |
| Depreciation and amortization | 116K USD | 137K USD | 126K USD | 118K USD | 72K USD |
| Operating income | −23.63M USD | −8.27M USD | −14.52M USD | −62.08M USD | −37.79M USD |
| Net income | −22.4M USD | −8.07M USD | −13.34M USD | −62.43M USD | −38.98M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$6.25
182.81% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI3.08M0.00%2.3T USD0.03%$379.73-0.32%
Vanguard Extended Market ETFVXF821.41K0.00%93.7B USD0.05%$242.66+0.14%
iShares Micro-Cap ETFIWC337.53K0.02%1.47B USD0.60%$196.25+0.69%
Avantis U.S. Small Cap Equity ETFAVSC167.41K0.01%3.11B USD0.25%$73.23+0.55%
Invesco NASDAQ Future Gen 200 ETFQQQS85.12K0.37%22.81M USD0.20%$44.7464+1.01%
U.S. Micro Cap Portfolio ETFDFMC17.02K0.00%7.81B USD0.43%$60.36+0.60%
Dimensional - US Small Cap ETFDFAS16.94K0.00%15.54B USD0.26%$82.20+0.18%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCAvantis U.S. Small Cap Equity ETFAVSCInvesco NASDAQ Future Gen 200 ETFQQQSU.S. Micro Cap Portfolio ETFDFMCDimensional - US Small Cap ETFDFASAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
